|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction显示文摘AIM: To evaluate the safety and technical success of endoscopic radiofrequency ablation(RFA) for palliative treatment of malignant hilar bile duct obstruction. METHODS: In this study, a recently CE and FDA-approved endoscopic RFA catheter was first tested in an ex vivo pig liver model to study the effect of electrosurgical variables on the extent of the area of induced necrosis. Subsequently, a retrospective analysis was conducted of all patients treated with endoscopic RFA for malignant biliary obstruction at our center between February 2012 and April 2013. All patients received an additional plastic stent implantation into the biliary tree following RFA. RESULTS: In the pig model, ablation time of 60-90 seconds using the bipolar soft coagulation mode at 8-10 watts with an effect of 8 was found to be the most feasible setting. Twelve patients(5 females, 7 males; mean age, 70 years) underwent 19 endoscopic RFA(range, 1-5) sessions. Deployment of RFA was successful in all patients. Systemic chemotherapy was administered in four patients. We observed biliary bleeding 4-6 wk after the intervention in three cases and two of these patients died: in one patient, spontaneous hemobilia occurred, whereas bleeding started during stent extraction in the other. In the third patient, bleeding was stopped by insertion of a non-covered self-expanding metal stent. Another three patients developed cholangitis during follow-up. Seven patients died during follow-up and median survival was 6.4 mo(95%CI: 0.05-12.7) from the time of the first RFA. CONCLUSION: Endoscopic RFA is an easy to perform and technically highly successful procedure. However, hemobilia possibly associated with RFA occurred in three of our patients. Therefore, larger prospective studies are needed to further evaluate the safety and efficacy of this promising new method. | Andrea Oliver Tal Johannes Vermehren Mireen FriedrichRust Jrg Bojunga Christoph Sarrazin Stefan Zeuzem Jrg Trojan Jrg Gerhard Albert | 2014 | World Journal of Gastrointestinal Endoscopy2014，6，1： | 18 |
| 2 | 2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B显示文摘 | Yun–Fan Liaw Edward Gane Nancy Leung Stefan Zeuzem Yuming Wang Ching Lung Lai E. Jenny Heathcote Michael Manns Natalie Bzowej Junqi Niu Steven–Huy Han Seong Gyu Hwang Yilmaz Cakaloglu Myron J. Tong George Papatheodoridis Yagang Chen Nathaniel A. Brown Efs | 2009 | Gastroenterology2009，，2： | 13 |
| 3 | Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis显示文摘 | Richard Moreau Rajiv Jalan Pere Gines Marco Pavesi Paolo Angeli Juan Cordoba Francois Durand Thierry Gustot Faouzi Saliba Marco Domenicali Alexander Gerbes Julia Wendon Carlo Alessandria Wim Laleman Stefan Zeuzem Jonel Trebicka Mauro Bernardi Vicente Arro | 2013 | Gastroenterology2013，，7： | 12 |
| 4 | Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis显示文摘 | Mireen Friedrich–Rust Mei–Fang Ong Swantje Martens Christoph Sarrazin Joerg Bojunga Stefan Zeuzem Eva Herrmann | 2008 | Gastroenterology2008，，4： | 6 |
| 5 | Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection显示文摘 | Nezam Afdhal Stefan Zeuzem Paul Kwo Mario Chojkier Norman Gitlin Massimo Puoti Manuel Romero-Gomez Jean-Pierre Zarski Kosh Agarwal Peter Buggisch Graham R. Foster Norbert Br?u Maria Buti Ira M. Jacobson G. Mani Subramanian Xiao Ding Hongmei Mo Jenny C. Ya | 2014 | The New England Journal of Medicine2014，，： | 6 |
| 6 | Influence of antibiotic-regimens on intensive-care unit-mortality and liver-cirrhosis as risk factor显示文摘AIM: To assess the rate of infection, appropriateness of antimicrobial-therapy and mortality on intensive care unit(ICU). Special focus was drawn on patients with liver cirrhosis.METHODS: The study was approved by the local ethical committee. All patients admitted to the Internal Medicine-ICU between April 1, 2007 and December 31, 2009 were included. Data were extracted retrospectively from all patients using patient charts and electronic documentations on infection, microbiological laboratory reports, diagnosis and therapy. Due to the large hepatology department and liver transplantation center, special interest was on the subgroup of patients with liver cirrhosis. The primary statistical-endpoint was the evaluation of the influence of appropriate versusinappropriate antimicrobial-therapy on in-hospitalmortality.RESULTS: Charts of 1979 patients were available. The overall infection-rate was 53%. Multiresistantbacteria were present in 23% of patients with infection and were associated with increased mortality(p < 0.000001). patients with infection had significantly increased in-hospital-mortality(34% vs 17%, p < 0.000001). Only 9% of patients with infection received inappropriate initial antimicrobial-therapy, no influence on mortality was observed. Independent risk-factors for in-hospital-mortality were the presence of septicshock, prior chemotherapy for malignoma and infection with pseudomonas spp. Infection and mortality-rate among 175 patients with liver-cirrhosis was significantly higher than in patients without liver-cirrhosis. Infection increased mortality 2.24-fold in patients with cirrhosis. patients with liver cirrhosis were at an increased risk to receive inappropriate initial antimicrobial therapy.CONCLUSION: The results of the present study report the successful implementation of early-goal-directed therapy. Liver cirrhosis patients are at increased risk of infection, mortality and to receive inappropriate therapy. Increasing burden are multiresistant-bacteria. | Mireen Friedrich-Rust Beate Wanger Florian Heupel Natalie Filmann Reinhard Brodt Volkhard AJ Kempf Johanna Kessel Thomas A Wichelhaus Eva Herrmann Stefan Zeuzem Joerg Bojunga | 2016 | World Journal of Gastroenterology2016，22，16： | 6 |
| 7 | Assessment of hemostatic profile in patients with mild to advanced liver cirrhosis显示文摘BACKGROUND Hemostasis of patients suffering from liver cirrhosis is challenging due to both,pro-and anticoagulatory disorders leading to hemostatic alterations with distinct abnormalities of coagulation.Pathological changes in conventional coagulation analysis and platelet count are common manifestations of decreased liver synthesis of coagulation factors and reduced platelet count in these patients.However,conventional coagulation analysis and platelet count do not reflect invivo coagulation status or platelet function.The purpose of this present observational study was therefore to assess the haemostatic profile including plasmatic coagulation using thrombelastometry and impedance aggregometry for platelet function in patients suffering from liver cirrhosis.AIM To assess the hemostatic profile of cirrhotic patients according to model for endstage liver disease(MELD)score.METHODS Our study included both in-and outpatients suffering from liver cirrhosis attending the out-and inpatient care of the department of hepatology.Demographic and biochemical data as well as medical history including cause of liver cirrhosis,end stage kidney failure and medication with anticoagulants were recorded.To assess the hemostatic profile,platelet function was analyzed by multiple electrode aggregometry(MEA)using Multiplate^■(ADP-,ASPI-and TRAP-test)and thrombelastometry using ROTEM^■(EXTEM,INTEM,FIBTEM).Data were compared using Mann-Whitney U-or χ^2-test.Spearman correlation was performed to analyze the association between MELD Score and results of thrombelastometry and MEA.RESULTS A total of 68 patients attending the out-and inpatient care suffering from liver cirrhosis were screened.Of these,50 patients were included and assigned to groups according to MELD score 6 to 11(n=25)or≥17(n=25).Baseline patient characteristics revealed significant differences for MELD score(8 vs 22,P<0.0001)and underlying laboratory parameters(international normalized ratio,bilirubine,creatinine)as well as fibrinogen level(275 mg/dL vs 209 mg/dL,P=0.006)and aPTT(30 s vs 35 s,P=0.047).MEA showed a moderately impaired platelet function(medians:AUCADP=43U,AUCASPI=71U,AUCTRAP=92U)but no significant differences between both groups.Thrombelastometry using ROTEM?(EXTEM,INTEM,FIBTEM)revealed values within normal range in both groups.No significant correlation was observed between MELD score and results of MEA/thrombelastometry.CONCLUSION Our data demonstrate a partially impaired hemostatic profile in liver cirrhosis patients unrelated to MELD score.An individual assessment of a potential coagulopathy should therefore be considered. | Elisabeth Hannah Adam Madara Mohlmann Eva Herrmann Sonia Schneider Kai Zacharowski Stefan Zeuzem Christian Friedrich Weber Nina Weiler | 2020 | World Journal of Gastroenterology2020，26，17： | 5 |
| 8 | Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir显示文摘 | Fred Poordad Jean–Pierre Bronowicki Stuart C. Gordon Stefan Zeuzem Ira M. Jacobson Mark S. Sulkowski Thierry Poynard Timothy R. Morgan Cliona Molony Lisa D. Pedicone Heather L. Sings Margaret H. Burroughs Vilma Sniukiene Navdeep Boparai Venkata S. Goteti | 2012 | Gastroenterology2012，，3： | 5 |
| 9 | SEMS vs cSEMS in duodenal and small bowel obstruction:High risk of migration in the covered stent group显示文摘AIM:To compare clinical success and complications of uncovered self-expanding metal stents(SEMS)vs covered SEMS(cSEMS)in obstruction of the small bowel.METHODS:Technical success,complications and outcome of endoscopic SEMS or cSEMS placement in tumor related obstruction of the duodenum or jejunum were retrospectively assessed.The primary end points were rates of stent migration and overgrowth.Secondary end points were the effect of concomitant biliary drainage on migration rate and overall survival.The data was analyzed according to the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.RESULTS:Thirty-two SEMS were implanted in 20 patients.In all patients,endoscopic stent implantation was successful.Stent migration was observed in 9 of16 cSEMS(56%)in comparison to 0/16 SEMS(0%)implantations(P=0.002).Stent overgrowth did not significantly differ between the two stent types(SEMS:3/16,19%;cSEMS:2/16,13%).One cSEMS dislodged and had to be recovered from the jejunum by way of laparotomy.Time until migration between SEMS and cSEMS in patients with and without concomitant biliary stents did not significantly differ(HR=1.530,95%CI0.731-6.306;P=0.556).The mean follow-up was 57±71 d(range:1-275 d).CONCLUSION:SEMS and cSEMS placement is safe in small bowel tumor obstruction.However,cSEMS is accompanied with a high rate of migration in comparison to uncovered SEMS. | Oliver Waidmann Jrg Trojan Mireen Friedrich-Rust Christoph Sarrazin Wolf Otto Bechstein Frank Ulrich Stefan Zeuzem Jrg Gerhard Albert | 2013 | World Journal of Gastroenterology2013，19，37： | 4 |
| 10 | FibroSURE^(TM) and FibroScan~ in relation to treatment response in chronic hepatitis C virus显示文摘AIM:To compare histological endpoint assessment using noninvasive alternatives to biopsy during treatment in a chronic hepatitis C virus(HCV)cohort.METHODS:Patients with chronic HCV were randomized to receive interferon-based therapy for 24(genotypes 2/3)or 48(genotype 1)wk.FibroSURE~TM(FS)was assessed at baseline and at week-12 post-treatment follow-up.Baseline biopsy for METAVIR was assessed by a single pathologist.FibroScan~ transient elastogra-phy(TE)was performed during treatment in a patient subset.RESULTS:Two thousand and sixty patients(n = 253 in Asia)were classif ied as METAVIR F0-1(n = 1682)or F2-4(n = 378).For F2-4,FS(n = 2055)had sensitiv-ity and specif icity of 0.87 and 0.61,respectively,with area under the receiver-operating curve of 0.82;corre-sponding values for TE(n = 214)and combined FS/TE(n = 209)were 0.77,0.88 and 0.88,and 0.93,0.68 and 0.88.Overall FS/TE agreement for F2-4 was 71%(κ = 0.41)and higher in Asians vs non-Asians(κ = 0.86 vs 0.35;P < 0.001).Combined FS/TE had 97% accuracy in Asians(n = 33).Baseline FS(0.38 vs 0.51,P < 0.001)and TE(8.0 kPa vs 11.9 kPa,P = 0.006)scores were lower in patients with sustained virological response than in nonresponders,and were maintained through follow-up.CONCLUSION:FS and TE may reliably differentiate mild from moderate-advanced disease,with a potential for high diagnostic accuracy in Asians with chronic HCV. | Keyur Patel Mireen Friedrich-Rust Yoav Lurie Mircea Grigorescu Carol Stanciu Chuan-Mo Lee Eugene R Schiff Dieter Hussinger Michael P Manns Guido Gerken Isabelle Colle Michael Torbenson Erik Pulkstenis G Mani Subramanian John G McHutchison Stefan Zeuzem | 2011 | World Journal of Gastroenterology2011，17，41： | 4 |
| 11 | A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin显示文摘 | Mark G. Swain Ming–Yang Lai Mitchell L. Shiffman W. Graham E. Cooksley Stefan Zeuzem Douglas T. Dieterich Armand Abergel Mário G. Pess?a Amy Lin Andreas Tietz Edward V. Connell Moisés Diago | 2010 | Gastroenterology2010，，5： | 3 |
| 12 | Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B显示文摘 | Milan J. Sonneveld Vincent W.–S. Wong Andrea M. Woltman Grace L.H. Wong Yilmaz Cakaloglu Stefan Zeuzem Erik H.C.J. Buster Andre G. Uitterlinden Bettina E. Hansen Henry L.Y. Chan Harry L.A. Janssen | 2012 | Gastroenterology2012，，3： | 3 |
| 13 | Contrast‐Enhanced Ultrasound for the differentiation of benign and malignant focal liver lesions: a meta‐analysis显示文摘 | Mireen Friedrich‐Rust Tom Klopffleisch Julia Nierhoff Eva Herrmann Johannes Vermehren Maximilian D. Schneider Stefan Zeuzem Joerg Bojunga | 2013 | Liver Int2013，，5： | 3 |
| 14 | Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection显示文摘 | Johannes Vermehren Simone Susser Annemarie Berger Dany Perner Kai-Henrik Peiffer Regina Allwinn Stefan Zeuzem Christoph Sarrazin | 2012 | Journal of Clinical Virology2012，，1： | 3 |
| 15 | Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection显示文摘Chronic hepatitis C is a major reason for development of cirrhosis and hepatocellular carcinoma and a leading cause for liver transplantation. The development of direct-acting antiviral agents lead to(pegylated) interferon-alfa free antiviral therapy regimens with a remarkable increase in sustained virologic response(SVR) rates and opened therapeutic options for patients with advanced cirrhosis and liver graft recipients. This concise review gives an overview about most current prospective trials and cohort analyses for treatment of patients with liver cirrhosis and liver graft recipients. In patients with compensated cirrhosis Child-Pugh-Turcotte(CTP) class A, all approved agents are safe and SVR rates do not significantly differ from patients without cirrhosis in general. In patients with decompensated cirrhosis CTP class B or C, daclastasvir, ledipasvir, velpatasvir, and sofosbuvir are approved, and SVR rates higher than 90% can be achieved. Especially for patients with a model of end stage liver disease score higher than 15 and therefore eligible for liver transplantation, data is scarce. Reported SVR rates in patients with cirrhosis CTP class C are lower compared to patients with a less severe liver disease. In liver transplant recipients with a maximum of CTP class A, SVR rates are comparable to patients without LT. Patients with decompensated graft cirrhosis should be treated on an individual basis. | Nina Weiler Stefan Zeuzem Martin-Walter Welker | 2016 | World Journal of Gastroenterology2016，22，41： | 2 |
| 16 | Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial显示文摘 | Harry LA Janssen Monika van Zonneveld Hakan Senturk Stefan Zeuzem Ulus S Akarca Yilmaz Cakaloglu Christopher Simon Thomas MK So Guido Gerken Robert A de Man Hubert GM Niesters Pieter Zondervan Bettina Hansen Solko W Schalm | 2005 | The Lancet . 2005 (9454)2005，，： | 2 |
| 17 | 聚乙二醇干扰素α-2a(40kD)和利巴韦林16周或24周治疗基因2型或3型慢性丙型肝炎患者 | Von Wagner M. Huber M. Berg T. S. Zeuzem 陈瑜 | 2005 | 世界核心医学期刊文摘(胃肠病学分册)2005，0，11： | 2 |
| 18 | 丙型肝炎患者接受telaprevir联合聚乙二醇干扰素+利巴韦林三联疗法所致贫血风险因素显示文摘直接作用抗病毒药(DAA)可抑制丙型肝炎病毒(HCV)基因1型复制,从而改善了初治和有过治疗史的丙肝患者持续病毒学应答(SVR)率。事实上,telaprevir 联合聚乙二醇干扰素+利巴韦林(PR)三联疗法相比 PR 二联疗法,治疗 HCV 基因1型慢性感染初治者已显示出了疗效的优越性。因而现有指南推荐使用 telaprevir 或 boceprevir+PR 方案。 | Zeuzem S DeMasi R Baldini A 本刊编辑部 | 2015 | 临床荟萃2015，30，1： | 2 |
| 19 | Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late显示文摘 | Adriano M. Pellicelli Marzia Montalbano Raffaella Lionetti Christine Durand Peter Ferenci Gianpiero D’Offizi Viola Knop Andrea Telese Ilaria Lenci Arnaldo Andreoli Stefan Zeuzem Mario Angelico | 2014 | Digestive and Liver Disease2014，，： | 2 |
| 20 | SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 Nonresponders显示文摘 | Christoph Sarrazin Regine Rouzier Frank Wagner Nicole Forestier Dominique Larrey Samir K. Gupta Musaddeq Hussain Amrik Shah David Cutler Jenny Zhang Stefan Zeuzem | 2007 | Gastroenterology2007，，4： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员